Anton Haselbeck und Roche Diagnostics - Info zur Person

(1 - 19 von 20

)

Epoetins: differences and their relevance to immunogenicityTaylor & Francis Online

www.tandfonline.com

von A Haselbeck · · Zitiert von: 63 — Epoetins: differences and their relevance to immunogenicity. Anton Haselbeck Roche Diagnostics GmbH, D Penzberg, Germany.

Herbert von der Eltz | Roche Diagnostics | 18 PublicationsTypeset

typeset.io

Anton Haselbeck 1, Edith Schickaneder 1, Herbert von der Eltz 1, Wolfgang Hösel 1• Institutions (1). Roche Diagnostics 1. › authors

Nonradioactive Analysis of Biomoleculesgoogle.de

books.google.de

... Anton Haselbeck , Roche Diagnostics GmbH , Pharma Research , Werk Penzberg , Nonnenwald 2 , Penzberg Germany ( phone + ; fax +

Abstract Author IndexThe National Kidney Foundation

www.kidney.org

Anton Haselbeck, Michael Brandt, Michael Jarsch; Roche Diagnostics GmbH, Penzberg,. Germany Chronic Kidney Disease Patients and Renal Transplant ... › files › CM07_Abstracts

Erythropoietin in the prevention of experimental burn ...Cicatrix e.V.

www.cicatrix.de

von M Tobalem · · Zitiert von: 30 — pathology work; and Anton Haselbeck (Roche Diagnostics,. Penzberg, Germany) and Pierre-Alain Delley (Roche. Pharma Schweiz, Reinach, Switzerland) for drug ...

Comparative Erythropoietin Receptor Binding Kinetics of ...ProQuest

search.proquest.com

von M Jarsch · · Zitiert von: 102 — Michael Jarsch Michael Brandt Martin Lanzendörfer Anton Haselbeck. Pharma Research, Roche Diagnostics GmbH, Penzberg , Germany. Introduction. › openview › 1.pdf

Erythropoietin-induced upregulation of endothelial nitric oxide ...swiss-knife.org

www.swiss-knife.org

von F Rezaeian · · Zitiert von: 57 — excellent technical assistance, and Anton Haselbeck (Roche Diagnostics. GmbH, Penzberg, Germany) and Pierre-Alain Delley (Roche Pharma ...

Erythropoietin-induced upregulation of endothelial nitric ...Nature Journal

www.nature.com

von F Rezaeian · · Zitiert von: 57 — ... and Anton Haselbeck (Roche Diagnostics GmbH, Penzberg, Germany) and Pierre-Alain Delley (Roche Pharma Schweiz, Reinach, Switzerland) for ...

CA A1 - Erythropoietin with high specific activity

patents.google.com

Priority to DE Application filed by Roche Diagnostics Gmbh, Josef Burg, Karl-Heinz Sellinger, Anton Haselbeck, Hans Koll.

Comparative Erythropoietin Receptor Binding Kinetics of ...ebsco

search.ebscohost.com

von M Jarsch · · Zitiert von: 104 — Michael Jarsch Michael Brandt Martin Lanzendörfer Anton Haselbeck. Pharma Research, Roche Diagnostics GmbH, Penzberg , Germany. Introduction.

Comparative erythropoietin receptor binding kinetics ...National Institutes of Health (.gov)

pubmed.ncbi.nlm.nih.gov

von M Jarsch · · Zitiert von: 104 — Authors. Michael Jarsch , Michael Brandt, Martin Lanzendörfer, Anton Haselbeck. Affiliation. 1 Pharma Research, Roche Diagnostics GmbH, Penzberg, ...

Epoetins: differences and their relevance to immunogenicityNational Institutes of Health (.gov)

pubmed.ncbi.nlm.nih.gov

von A Haselbeck · · Zitiert von: 63 — Anton Haselbeck. Affiliation. 1 Roche Diagnostics GmbH, D Penzberg, Germany. . PMID: ; DOI:

Erythropoietin-induced upregulation of endothelial nitric oxide ...

www.academia.edu

Evolution of ischemic tissue injury in a excellent technical assistance, and Anton Haselbeck (Roche Diagnostics random pattern flap: a new mouse model using ... › Erythr...

The next move in biopharmaSociety of Chemical Industry

www.soci.org

Anton Haselbeck, head of new technologies at Roche Diagnostics, says that Roche, which is not developing biosimilars, is also not pursuing biobetters as a ...